Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: CD276

Gene summary for CD276

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

CD276

Gene ID

80381

Gene nameCD276 molecule
Gene Alias4Ig-B7-H3
Cytomap15q24.1
Gene Typeprotein-coding
GO ID

GO:0001775

UniProtAcc

Q5ZPR3


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
80381CD276LZE4THumanEsophagusESCC1.01e-061.99e-010.0811
80381CD276LZE7THumanEsophagusESCC6.11e-063.40e-010.0667
80381CD276LZE24THumanEsophagusESCC2.28e-067.36e-020.0596
80381CD276P1T-EHumanEsophagusESCC1.30e-063.57e-010.0875
80381CD276P2T-EHumanEsophagusESCC6.68e-266.84e-010.1177
80381CD276P4T-EHumanEsophagusESCC1.21e-236.38e-010.1323
80381CD276P5T-EHumanEsophagusESCC6.30e-031.16e-010.1327
80381CD276P8T-EHumanEsophagusESCC3.41e-254.42e-010.0889
80381CD276P9T-EHumanEsophagusESCC1.36e-123.62e-010.1131
80381CD276P10T-EHumanEsophagusESCC1.73e-306.20e-010.116
80381CD276P11T-EHumanEsophagusESCC3.41e-178.66e-010.1426
80381CD276P12T-EHumanEsophagusESCC6.36e-244.25e-010.1122
80381CD276P15T-EHumanEsophagusESCC3.45e-255.43e-010.1149
80381CD276P16T-EHumanEsophagusESCC2.28e-439.84e-010.1153
80381CD276P17T-EHumanEsophagusESCC2.22e-064.32e-010.1278
80381CD276P19T-EHumanEsophagusESCC2.06e-111.43e+000.1662
80381CD276P20T-EHumanEsophagusESCC1.61e-071.95e-010.1124
80381CD276P21T-EHumanEsophagusESCC1.45e-257.24e-010.1617
80381CD276P22T-EHumanEsophagusESCC2.29e-285.80e-010.1236
80381CD276P23T-EHumanEsophagusESCC6.85e-195.03e-010.108
Page: 1 2 3 4 5 6 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:004578527EsophagusESCCpositive regulation of cell adhesion255/8552437/187235.07e-089.11e-07255
GO:002240720EsophagusESCCregulation of cell-cell adhesion239/8552448/187235.88e-043.19e-03239
GO:004211018EsophagusESCCT cell activation256/8552487/187231.18e-035.87e-03256
GO:002240919EsophagusESCCpositive regulation of cell-cell adhesion155/8552284/187231.50e-037.06e-03155
GO:00508528EsophagusESCCT cell receptor signaling pathway73/8552123/187231.54e-037.24e-0373
GO:000181916EsophagusESCCpositive regulation of cytokine production244/8552467/187232.29e-031.01e-02244
GO:005087015EsophagusESCCpositive regulation of T cell activation117/8552216/187237.23e-032.62e-02117
GO:190303916EsophagusESCCpositive regulation of leukocyte cell-cell adhesion128/8552239/187238.40e-032.96e-02128
GO:000715918EsophagusESCCleukocyte cell-cell adhesion192/8552371/187231.03e-023.51e-02192
GO:190303717EsophagusESCCregulation of leukocyte cell-cell adhesion174/8552336/187231.36e-024.43e-02174
GO:004578512LiverHCCpositive regulation of cell adhesion215/7958437/187232.53e-031.22e-02215
GO:004578520Oral cavityOSCCpositive regulation of cell adhesion225/7305437/187236.06e-081.09e-06225
GO:004211016Oral cavityOSCCT cell activation245/7305487/187232.00e-073.22e-06245
GO:002240718Oral cavityOSCCregulation of cell-cell adhesion218/7305448/187231.71e-051.68e-04218
GO:005086315Oral cavityOSCCregulation of T cell activation161/7305329/187231.44e-041.02e-03161
GO:00508527Oral cavityOSCCT cell receptor signaling pathway68/7305123/187231.80e-041.22e-0368
GO:000715916Oral cavityOSCCleukocyte cell-cell adhesion178/7305371/187232.44e-041.57e-03178
GO:190303715Oral cavityOSCCregulation of leukocyte cell-cell adhesion162/7305336/187233.39e-042.08e-03162
GO:004209816Oral cavityOSCCT cell proliferation100/7305199/187237.93e-044.27e-03100
GO:002240917Oral cavityOSCCpositive regulation of cell-cell adhesion136/7305284/187231.35e-036.62e-03136
Page: 1 2 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
CD276SNVMissense_Mutationnovelc.1043N>Cp.Gly348Alap.G348AQ5ZPR3protein_codingtolerated(0.2)benign(0.349)TCGA-A7-A6VY-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapycyclophosphamideCR
CD276SNVMissense_Mutationc.787N>Ap.Asp263Asnp.D263NQ5ZPR3protein_codingdeleterious(0.02)possibly_damaging(0.74)TCGA-D8-A27G-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
CD276insertionIn_Frame_Insnovelc.308_309insCCTp.Gly103_Asn104insLeup.G103_N104insLQ5ZPR3protein_codingTCGA-A8-A08H-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
CD276insertionFrame_Shift_Insnovelc.310_311insCCACCATATTTAAAGGTp.Asn104ThrfsTer10p.N104Tfs*10Q5ZPR3protein_codingTCGA-A8-A08H-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
CD276deletionFrame_Shift_Delnovelc.146delNp.Cys49SerfsTer21p.C49Sfs*21Q5ZPR3protein_codingTCGA-EW-A2FV-01Breastbreast invasive carcinomaFemale<65III/IVChemotherapydocetaxelSD
CD276SNVMissense_Mutationrs141119771c.334N>Ap.Val112Metp.V112MQ5ZPR3protein_codingdeleterious(0)probably_damaging(0.963)TCGA-EA-A3HS-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
CD276SNVMissense_Mutationrs562558740c.274N>Tp.Arg92Cysp.R92CQ5ZPR3protein_codingdeleterious(0)probably_damaging(0.998)TCGA-ZX-AA5X-01Cervixcervical & endocervical cancerFemale<65III/IVUnknownUnknownSD
CD276insertionIn_Frame_Insnovelc.709_710insGGGp.Ile237delinsArgValp.I237delinsRVQ5ZPR3protein_codingTCGA-DS-A1OB-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycarboplatinPD
CD276SNVMissense_Mutationrs562558740c.274N>Tp.Arg92Cysp.R92CQ5ZPR3protein_codingdeleterious(0)probably_damaging(0.998)TCGA-A6-5661-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
CD276SNVMissense_Mutationc.1585G>Tp.Asp529Tyrp.D529YQ5ZPR3protein_codingdeleterious_low_confidence(0)possibly_damaging(0.907)TCGA-AA-3510-01Colorectumcolon adenocarcinomaMale>=65I/IIUnknownUnknownSD
Page: 1 2 3 4 5 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
80381CD276CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOMEantibody340590220ENOBLITUZUMAB
80381CD276CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOMEN/A
80381CD276CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOMEMGD009
80381CD276CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOMEMGA271ENOBLITUZUMAB23114578
80381CD276CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME124I-8H9
80381CD276CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOMEOmburtamab I-131
80381CD276CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOMEOmburtamab I-124
80381CD276CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOMEEnoblituzumabENOBLITUZUMAB
Page: 1